Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i> –Induced B-Cell Acute Lymphoblastic Leukemia
Linyu Yang(Sichuan University), Lijuan Chen(State Key Laboratory of Biotherapy), Liya Luo(Sichuan University), Liping Gou(Sichuan University), Yuyao Yi(Sichuan University), Minghai Tang(Sichuan University), Yiguo Hu(Sichuan University), Shoujun Zheng(Beijing Institute of Technology), Dongni Yi(Sichuan University), Ting Niu(Sichuan University), Haoyu Ye(State Key Laboratory of Biotherapy), Heying Pei(Sichuan University), Fang Wang(Shanghai Tenth People's Hospital), Li Zheng(Sichuan University), Yong Chen(Sichuan University), Xing Deng(Sichuan University), Zejiang Zhu(Sichuan University), Zhuang Yang(Sichuan University), Qiang Qiu(Sichuan University), Jianhong Yang(Sichuan University)
Cited by 19
Related Papers
Highly Sensitive Detection of Polarized Light Using Anisotropic 2D ReS<sub>2</sub>
|Advanced Functional Materials|2016|522
Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
|Chemistry & Biology|2013|498
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
|Cancer Discovery|2017|457
SARS-CoV-2 M <sup>pro</sup> inhibitors with antiviral activity in a transgenic mouse model
|Science|2021|449
In-sensor reservoir computing for language learning via two-dimensional memristors
|Science Advances|2021|420